Table of Contents
Journal of Signal Transduction
Volume 2011 (2011), Article ID 718609, 9 pages
http://dx.doi.org/10.1155/2011/718609
Review Article

Relevance of VEGF and Nephrin Expression in Glomerular Diseases

Department of Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, PA 15261, USA

Received 16 March 2011; Accepted 25 May 2011

Academic Editor: Mira Krendel

Copyright © 2011 Claudia A. Bertuccio. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Haraldsson, J. Nystrom, and W. M. Deen, “Properties of the glomerular barrier and mechanisms of proteinuria,” Physiological Reviews, vol. 88, no. 2, pp. 451–487, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. Jeansson and B. Haraldsson, “Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier,” American Journal of Physiology, vol. 290, no. 1, pp. F111–F116, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. D. R. Abrahamson, “Structure and development of the glomerular capillary wall and basement membrane,” American Journal of Physiology, vol. 253, no. 2, pp. F783–F794, 1987. View at Google Scholar · View at Scopus
  4. T. Pihlajaniemi, “Molecular properties of the glomerular basement membrane,” Contributions to Nephrology, vol. 117, pp. 46–79, 1996. View at Google Scholar · View at Scopus
  5. R. Timpl and J. C. Brown, “Supramolecular assembly of basement membranes,” Bioessays, vol. 18, no. 2, pp. 123–132, 1996. View at Google Scholar · View at Scopus
  6. J. Reiser, W. Kriz, M. Kretzler, and P. Mundel, “The glomerular slit diaphragm is a modified adherens junction,” Journal of the American Society of Nephrology, vol. 11, no. 1, pp. 1–8, 2000. View at Google Scholar · View at Scopus
  7. D. Kerjaschki, D. J. Sharkey, and M. G. Farquhar, “Identification and characterization of podocalyxin, the major sialoprotein of the renal glomerular epithelial cell,” Journal of Cell Biology, vol. 98, no. 4, pp. 1591–1596, 1984. View at Google Scholar · View at Scopus
  8. J. A. Kreidberg, M. J. Donovan, S. L. Goldstein et al., “α 3 β 1 integrin has a crucial role in kidney and lung organogenesis,” Development, vol. 122, no. 11, pp. 3537–3547, 1996. View at Google Scholar · View at Scopus
  9. C. J. Raats, J. van den Born, M. A. Bakker et al., “Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies,” American Journal of Pathology, vol. 156, no. 5, pp. 1749–1765, 2000. View at Google Scholar · View at Scopus
  10. D. Drenckhahn and R. F. Franke, “Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man,” Laboratory Investigation, vol. 59, no. 5, pp. 673–682, 1988. View at Google Scholar · View at Scopus
  11. Y. S. Kanwar, Z. Z. Liu, N. Kashihara, and E. I. Wallner, “Current status of the structural and functional basis of glomerular filtration and proteinuria,” Seminars in Nephrology, vol. 11, no. 4, pp. 390–413, 1991. View at Google Scholar · View at Scopus
  12. M. Kestilä, U. Lenkkeri, M. Männikkö et al., “Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome,” Molecular Cell, vol. 1, no. 4, pp. 575–582, 1998. View at Google Scholar · View at Scopus
  13. V. Ruotsalainen, P. Ljungberg, J. Wartiovaara et al., “Nephrin is specifically located at the slit diaphragm of glomerular podocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 6, no. 14, pp. 7962–7967, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Tryggvason, “Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm,” Journal of the American Society of Nephrology, vol. 10, no. 11, pp. 2440–2445, 1999. View at Google Scholar · View at Scopus
  15. K. Yan, J. Khoshnoodi, V. Ruotsalainen, and K. Tryggvason, “N-linked glycosylation is critical for the plasma membrane localization of nephrin,” Journal of the American Society of Nephrology, vol. 13, no. 5, pp. 1385–1389, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Gerke, T. B. Huber, L. Sellin, T. Benzing, and G. Walz, “Homodimerization and heterodimerization of the glomerular podocyte proteins nephrin and NEPH1,” Journal of the American Society of Nephrology, vol. 14, no. 4, pp. 918–926, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Wartiovaara, L. G. Ofverstedt, J. Khoshnoodi et al., “Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography,” Journal of Clinical Investigation, vol. 114, no. 10, pp. 1475–1483, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Putaala, K. Sainio, H. Sariola, and K. Tryggvason, “Primary structure of mouse and rat nephrin cDNA and structure and expression of the mouse gene,” Journal of the American Society of Nephrology, vol. 11, no. 6, pp. 991–1001, 2000. View at Google Scholar · View at Scopus
  19. R. Verma, B. Wharram, I. Kovari et al., “Fyn binds to and phosphorylates the kidney slit diaphragm component nephrin,” Journal of Biological Chemistry, vol. 278, no. 23, pp. 20716–20723, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. B. Huber, B. Hartleben, J. Kim et al., “Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling,” Molecular and Cellular Biology, vol. 23, no. 14, pp. 4917–4928, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Jones, I. M. Blasutig, V. Eremina et al., “Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes,” Nature, vol. 6, no. 7085, pp. 818–823, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. H. Putaala, R. Soininen, P. Kilpeläinen, J. Wartiovaara, and K. Tryggvason, “The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death,” Human Molecular Genetics, vol. 10, no. 1, pp. 1–8, 2001. View at Google Scholar · View at Scopus
  23. H. Holthöfer, H. Ahola, M. L. Solin et al., “Nephrin localizes at the podocyte filtration slit area and is characteristically spliced in the human kidney,” American Journal of Pathology, vol. 155, no. 5, pp. 1681–1687, 1999. View at Google Scholar · View at Scopus
  24. J. Patrakka, M. Kestilä, J. Wartiovaara et al., “Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in finnish patients,” Kidney International, vol. 58, no. 3, pp. 972–980, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. C. Holmberg, M. Antikainen, K. Rönnholm, M. Ala-Houhala, and H. Jalanko, “Management of congenital nephrotic syndrome of the finnish type,” Pediatric Nephrology, vol. 9, no. 1, pp. 87–93, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Inoue, E. Yaoita, H. Kurihara et al., “FAT is a component of glomerular slit diaphragms,” Kidney International, vol. 59, no. 3, pp. 1001–1012, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. E. Schnabel, M. Anderson, and M. G. Farquhar, “The tight junction protein ZO-1 is concentrated along slit diaphragms of the glomerular epithelium,” Journal of Cell Biology, vol. 111, no. 3, pp. 255–263, 1990. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Y. Shi, J. Li, R. Cotran, P. Mundel, J. H. Miner, and A. S. Shaw, “CD2AP localizes to the slit diaphragm and binds to nephrin via a novel C-terminal domain,” American Journal of Pathology, vol. 159, no. 6, pp. 2303–2308, 2001. View at Google Scholar · View at Scopus
  29. N. Y. Shih, J. Li, V. Karpitskii et al., “Congenital nephrotic syndrome in mice lacking CD2-associated protein,” Science, vol. 286, no. 5438, pp. 312–315, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Schwarz, M. Simons, J. Reiser et al., “Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin,” Journal of Clinical Investigation, vol. 108, no. 11, pp. 1621–1629, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. T. B. Huber, M. Köttgen, B. Schilling, G. Walz, and T. Benzing, “Interaction with Podocin facilitates nephrin signaling,” Journal of Biological Chemistry, vol. 276, no. 45, pp. 41543–41546, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. S. Lehtonen, F. Zhao, and E. Lehtonen, “CD2-associated protein directly interacts with the actin cytoskeleton,” American Journal of Physiology, vol. 283, no. 4, pp. F734–F743, 2002. View at Google Scholar · View at Scopus
  33. L. Sellin, T. B. Huber, P. Gerke, I. Quack, H. Pavenstädt, and G. Walz, “NEPH1 defines a novel family of podocin interacting proteins,” FASEB Journal, vol. 17, no. 1, pp. 115–117, 2003. View at Google Scholar · View at Scopus
  34. T. B. Huber, M. Schmidts, P. Gerke et al., “The carboxyl terminus of neph family members binds to the PDZ domain protein zonula occludens-1,” Journal of Biological Chemistry, vol. 278, no. 15, pp. 13417–13421, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. J. Reiser, K. R. Polu, C. C. Möller et al., “TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function,” Nature Genetics, vol. 37, no. 7, pp. 739–744, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. D. B. Donoviel, D. D. Freed, H. Vogel et al., “Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN,” Molecular and Cellular Biology, vol. 21, no. 14, pp. 4829–4836, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. N. Boute, O. Gribouval, S. Roselli et al., “NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome,” Nature Genetics, vol. 24, no. 4, pp. 349–354, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. L. Ciani, A. Patel, N. D. Allen, and C. Ffrench-Constant, “Mice lacking the giant protocadherin mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia phenotype,” Molecular and Cellular Biology, vol. 23, no. 10, pp. 3575–3582, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. S. J. Shankland, “The podocyte's response to injury: role in proteinuria and glomerulosclerosis,” Kidney International, vol. 69, no. 12, pp. 2131–2147, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. J. M. Kaplan, S. H. Kim, K. N. North et al., “Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis,” Nature Genetics, vol. 24, no. 3, pp. 251–256, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. R. Doyonnas, D. B. Kershaw, C. Duhme et al., “Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin,” Journal of Experimental Medicine, vol. 194, no. 1, pp. 13–27, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Eremina, H. J. Baelde, and S. E. Quaggin, “Role of the VEGF—a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier,” Nephron Physiology, vol. 106, no. 2, pp. p32–p37, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. J. C. Yang, L. Haworth, R. M. Sherry et al., “A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,” New England Journal of Medicine, vol. 349, no. 5, pp. 427–434, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. F. Kabbinavar, H. I. Hurwitz, L. Fehrenbacher et al., “Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 60–65, 2003. View at Google Scholar · View at Scopus
  45. V. Eremina, J. A. Jefferson, J. Kowalewska et al., “VEGF inhibition and renal thrombotic microangiopathy,” New England Journal of Medicine, vol. 358, no. 11, pp. 1129–1136, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. T. Patel, J. Morgan, G. Demetri et al., “A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib,” Journal of the National Cancer Institute, vol. 100, no. 4, pp. 282–284, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. S. E. Maynard, J. Y. Min, J. Merchan et al., “Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 649–658, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Müller-Deile and M. Schiffer, “Renal involvement in preeclampsia: similarities to VEGF ablation therapy,” Journal of Pregnancy, vol. 2011, Article ID 176973, 6 pages, 2011. View at Publisher · View at Google Scholar · View at PubMed
  49. H. Sugimoto, Y. Hamanog, D. Charytan et al., “Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria,” Journal of Biological Chemistry, vol. 278, no. 15, pp. 12605–12608, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak, “Vascular endothelial growth factor (VEGF) and its receptors,” FASEB Journal, vol. 13, no. 1, pp. 9–22, 1999. View at Google Scholar · View at Scopus
  51. M. Simon, H. J. Gröne, O. Jöhren et al., “Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney,” American Journal of Physiology, vol. 268, no. 2, pp. F240–F250, 1995. View at Google Scholar · View at Scopus
  52. M. Simon, W. Rockl, C. Hornig et al., “Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites,” Journal of the American Society of Nephrology, vol. 9, no. 6, pp. 1032–1044, 1998. View at Google Scholar · View at Scopus
  53. K. Kondo, S. Hiratsuka, E. Subbalakshmi, H. Matsushime, and M. Shibuya, “Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) Receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors,” Gene, vol. 208, no. 2, pp. 297–305, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Shibuya, S. Yamaguchi, A. Yamane et al., “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely relatd to the fms family,” Oncogene, vol. 8, no. 4, pp. 519–524, 1990. View at Google Scholar · View at Scopus
  55. B. I. Terman, M. E. Carrion, E. Kovacs, B. A. Rasmussen, R. L. Eddy, and T. B. Shows, “Identification of a new endothelial cell growth factor receptor tyrosine kinase,” Oncogene, vol. 6, no. 9, pp. 1677–1683, 1991. View at Google Scholar · View at Scopus
  56. J. Schlessinger, “Cell signaling by receptor tyrosine kinases,” Cell, vol. 103, no. 2, pp. 211–225, 2000. View at Google Scholar · View at Scopus
  57. E. Sulpice, J. Plouët, M. Bergé, D. Allanic, G. Tobelem, and T. Merkulova-Rainon, “Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity,” Blood, vol. 111, no. 4, pp. 2036–2045, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. Y. Shaked, G. Bocci, R. Munoz et al., “Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose,” Current Cancer Drug Targets, vol. 5, no. 7, pp. 551–559, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. R. L. Kendall and K. A. Thomas, “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 22, pp. 10705–10709, 1993. View at Publisher · View at Google Scholar · View at Scopus
  60. J. E. Park, H. H. Chen, J. Winer, K. A. Houck, and N. Ferrara, “Placenta growth factor. potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR,” Journal of Biological Chemistry, vol. 269, no. 41, pp. 25646–25654, 1994. View at Google Scholar · View at Scopus
  61. K. A. Houck, N. Ferrara, J. Winer, G. Cachianes, B. Li, and D. W. Leung, “The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA,” Molecular Endocrinology, vol. 5, no. 12, pp. 1806–1814, 1991. View at Google Scholar · View at Scopus
  62. D. Bates, T. Cui, J. Doughty et al., “VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma,” Cancer Research, vol. 62, no. 14, pp. 4123–4131, 2002. View at Google Scholar · View at Scopus
  63. H. Kawamura, X. Li, K. Goishi et al., “Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization,” Blood, vol. 112, no. 9, pp. 3638–3649, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. T. Cui, R. Foster, M. Saleem et al., “Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein,” American Journal of Physiology, vol. 286, no. 4, pp. F767–F773, 2004. View at Google Scholar · View at Scopus
  65. V. A. Schumacher, S. Jeruschke, F. Eitner et al., “Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome,” Journal of the American Society of Nephrology, vol. 18, no. 3, pp. 719–729, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. H. Bevan, N. van den Akker, Y. Qiu et al., “The alternatively spliced anti-angiogenic family of VEGF isoforms VEGF xxxb in human kidney development,” Nephron Physiology, vol. 110, no. 4, pp. p57–p67, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. S. Cébe Suarez, M. Pieren, L. Cariolato et al., “A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2,” Cellular and Molecular Life Sciences, vol. 63, no. 17, pp. 2067–2077, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. S. J. Harper and D. Bates, “VEGF-A splicing: the key to anti-angiogenic therapeutics?” Nature Reviews Cancer, vol. 8, no. 11, pp. 880–887, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. J. Woolard, W. Wang, H. Bevan et al., “VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression,” Cancer Research, vol. 64, no. 21, pp. 7822–7835, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. A. Varey, E. Rennel, Y. Qiu et al., “VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy,” British Journal of Cancer, vol. 98, no. 8, pp. 1366–1379, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. R. Pritchard-Jones, D. Dunn, Y. Qiu et al., “Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma,” British Journal of Cancer, vol. 97, no. 2, pp. 223–230, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. D. Bates, P. MacMillan, J. Manjaly et al., “The endogenous anti-angiogenic family of splice variants of VEGF, VEGF xxxb, are down-regulated in pre-eclamptic placentae at term,” Clinical Science, vol. 110, no. 5, pp. 575–585, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. N. H. Kim, J. H. Oh, J. A. Seo et al., “Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy,” Kidney International, vol. 67, no. 1, pp. 167–177, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. D. R. Cha, Y. S. Kang, S. Y. Han et al., “Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats,” Journal of Endocrinology, vol. 183, no. 1, pp. 183–194, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. M. E. Cooper, D. Vranes, S. Youssef et al., “Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes,” Diabetes, vol. 48, no. 11, pp. 2229–2239, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. B. F. Schrijvers, A. Flyvbjerg, and A. S. De Vriese, “The role of vascular endothelial growth factor (VEGF) in renal pathophysiology,” Kidney International, vol. 65, no. 6, pp. 2003–2017, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. S. Chen, J. S. Lee, M. C. Iglesias-de la Cruz et al., “Angiotensin II stimulates α3(IV) collagen production in mouse podocytes via TGF-β and VEGF signalling: implications for diabetic glomerulopathy,” Nephrology Dialysis Transplantation, vol. 20, no. 7, pp. 1320–1328, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. B. F. Schrijvers, A. Flyvbjerg, R. G. Tilton, N. H. Lameire, and A. S. De Vriese, “A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat,” Nephrology Dialysis Transplantation, vol. 21, no. 2, pp. 324–329, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. Y. Horita, M. Miyazaki, T. Koji et al., “Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis,” Nephrology Dialysis Transplantation, vol. 13, no. 10, pp. 2519–2528, 1998. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Matsumoto and K. Kanmatsuse, “Elevated vascular endothelial growth factor levels in the urine of patients with minimal-change nephrotic syndrome,” Clinical Nephrology, vol. 55, no. 4, pp. 269–274, 2001. View at Google Scholar · View at Scopus
  81. E. Bailey, M. J. Bottomley, S. Westwell et al., “Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation,” Journal of Clinical Pathology, vol. 52, pp. 735–738, 1999. View at Google Scholar
  82. A. Kaukinen, A. Kuusniemi, I. Lautenschlager, and H. Jalanko, “Glomerular endothelium in kidneys with congenital nephrotic syndrome of the finnish type (NPHS1),” Nephrology Dialysis Transplantation, vol. 23, no. 4, pp. 1224–1232, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. B. Hohenstein, M. Colin, C. Foellmer et al., “Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans,” Nephrology Dialysis Transplantation, vol. 25, no. 10, pp. 3170–3180, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. E. Honkanen, A. Teppo, and C. Gronhagen-Riska, “Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis,” Kidney International, vol. 57, no. 6, pp. 2343–2349, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. A. Kubo, Y. Nishitani, N. Minamino et al., “Adrenomedullin gene transcription is decreased in peripheral blood mononuclear cells of patients with IgA nephropathy,” Nephron, vol. 85, no. 3, pp. 201–206, 2000. View at Google Scholar · View at Scopus
  86. A. Amore, G. Conti, P. Cirina et al., “Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells,” American Journal of Kidney Diseases, vol. 36, no. 6, pp. 1242–1252, 2000. View at Google Scholar · View at Scopus
  87. H. T. Yuan, P. G. Tipping, X. Z. Li, D. A. Long, and A. S. Woolf, “Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis,” Kidney International, vol. 61, no. 6, pp. 2078–2089, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. J. Müller-Deile, V. Bröcker, V. Grünwald et al., “Renal side effects of VEGF-blocking therapy,” NDT Plus, vol. 3, no. 2, pp. 172–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. Q. Fan, Y. Xing, J. Ding, and N. Guan, “Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats,” Nephron, vol. 111, no. 4, pp. e92–e102, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. L. Fan, T. Wakayama, S. Yokoyama, O. Amano, and S. Iseki, “Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis,” Nephron, vol. 90, no. 1, pp. 95–102, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. V. Eremina, M. Sood, J. Haigh et al., “Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 707–716, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. N. Ferrara, K. Carver-Moore, H. Chen et al., “Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene,” Nature, vol. 380, no. 6573, pp. 439–442, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. P. Carmeliet, V. Ferreira, G. Breier et al., “Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele,” Nature, vol. 380, no. 6573, pp. 435–439, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. Y. Kitamoto, H. Tokunaga, and K. Tomita, “Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis,” Journal of Clinical Investigation, vol. 99, no. 10, pp. 2351–2357, 1997. View at Google Scholar · View at Scopus
  95. P. Aaltonen, P. Luimula, E. Åström et al., “Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy,” Laboratory Investigation, vol. 81, no. 9, pp. 1185–1190, 2001. View at Google Scholar · View at Scopus
  96. S. Doublier, G. Salvidio, E. Lupia et al., “Nephrin expression is reduced in human diabetic nephropathy,” Diabetes, vol. 51, no. 4, pp. 1023–1030, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Benigni, E. Gagliardini, S. Tomasoni et al., “Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy,” Kidney International, vol. 65, no. 6, pp. 2193–2200, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. M. Toyoda, D. Suzuki, T. Umezono et al., “Expression of human nephrin mRNA in diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 19, no. 2, pp. 380–385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Cohen, S. Chen, F. Ziyadeh et al., “Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy,” Kidney International, vol. 68, no. 4, pp. 1554–1561, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. L. Chun-Liang, W. Feng-Sheng, H. Yen-Chen et al., “Modulation of Notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy,” Diabetes, vol. 59, no. 8, pp. 1915–1925, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. V. Garovic, S. Wagner, L. Petrovic et al., “Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia,” Nephrology Dialysis Transplantation, vol. 22, no. 4, pp. 1136–1143, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. K. Koop, M. Eikmans, H. J. Baelde et al., “Expression of podocyte-associated molecules in acquired human kidney diseases,” Journal of the American Society of Nephrology, vol. 14, no. 8, pp. 2063–2071, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. A. Fukuda, S. Fujimoto, S. Iwatsubo, H. Kawachi, and K. Kitamura, “Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome,” Nephrology, vol. 15, no. 3, pp. 321–326, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. J. Mao, Y. Zhang, L. Du, Y. Dai, C. Yang, and L. Liang, “Expression profile of nephrin, podocin, and CD2AP in chinese children with MCNS and IgA nephropathy,” Pediatric Nephrology, vol. 21, no. 11, pp. 1666–1675, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. A. T. Lahdenkari, M. Kestilä, C. Holmberg, O. Koskimies, and H. Jalanko, “Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS),” Kidney International, vol. 65, no. 5, pp. 1856–1863, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  106. A. Shono, H. Tsukaguchi, A. Kitamura et al., “Predisposition to relapsing nephrotic syndrome by a nephrin mutation that interferes with assembly of functioning microdomains,” Human Molecular Genetics, vol. 18, no. 16, pp. 2943–2956, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. P. N. Furness, L. L. Hall, J. A. Shaw, and J. H. Pringle, “Glomerular expression of nephrin is decreased in acquired human nephritic syndrome,” Nephrology Dialysis Transplantation, vol. 14, pp. 1234–1237, 1999. View at Google Scholar
  108. W. Huh, D. J. Kim, M. K. Kim et al., “Expression of nephrin in acquired human glomerular disease,” Nephrology Dialysis Transplantation, vol. 17, no. 3, pp. 478–484, 2002. View at Google Scholar · View at Scopus
  109. T. Srivastava, J. M. Whiting, R. E. Garola et al., “Podocyte proteins in galloway-mowat syndrome,” Pediatric Nephrology, vol. 16, no. 12, pp. 1022–1029, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. S. X. Wang, M. P. Rastaldi, A. Patari, H. Ahola, E. Heikkila, and H. Holthofer, “Patterns of nephrin and a new proteinuria-associated protein expression in human renal diseases,” Kidney International, vol. 61, pp. 141–147, 2002. View at Google Scholar
  111. S. Doublier, V. Ruotsalainen, G. Salvidio et al., “Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome,” American Journal of Pathology, vol. 158, no. 5, pp. 1723–1731, 2001. View at Google Scholar · View at Scopus
  112. J. Patrakka, V. Ruotsalainen, I. Ketola et al., “Expression of nephrin in pediatric kidney diseases,” Journal of the American Society of Nephrology, vol. 12, no. 2, pp. 289–296, 2001. View at Google Scholar · View at Scopus
  113. N. Guan, J. Ding, J. Zhang, and J. Yang, “Expression of nephrin, podocin, α-actinin, and WT1 in children with nephritic syndrome,” Pediatric Nephrology, vol. 18, pp. 1122–1127, 2003. View at Google Scholar
  114. S. R. Hingorani, L. S. Finn, J. Kowalewska, R. A. McDonald, and A. A. Eddy, “Expression of nephrin in acquired forms of nephritic syndrome in childhood,” Pediatric Nephrology, vol. 19, pp. 300–305, 2004. View at Google Scholar
  115. A. Hara, T. Wada, K. Furuichi et al., “Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis,” Kidney International, vol. 69, no. 11, pp. 1986–1995, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. T. Nakatsue, H. Koike, G. D. Han et al., “Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy,” Kidney International, vol. 67, no. 6, pp. 2239–2253, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  117. H. Yuan, E. Takeuchi, G. A. Taylor, M. Mclaughlin, D. Brown, and D. J. Salant, “Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy,” Journal of the American Society of Nephrology, vol. 13, no. 4, pp. 946–956, 2002. View at Google Scholar · View at Scopus
  118. D. R. Abrahamson, “Glomerulogenesis in the developing kidney,” Seminars in Nephrology, vol. 11, no. 4, Article ID 1947493, pp. 375–389, 1991. View at Google Scholar
  119. M. Ohlson, J. Sörensson, K. Lindström, A. M. Blom, E. Fries, and B. Haraldsson, “Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules,” American Journal of Physiology, vol. 281, no. 1, pp. F103–F113, 2001. View at Google Scholar · View at Scopus
  120. K. Sison, V. Eremina, H. Baelde et al., “Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling,” Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1691–1701, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  121. R. R. Foster, M. Saleem, P. Mathieson, D. Bates, and S. Harper, “Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes,” American Journal of Physiology, vol. 288, no. 1, pp. F48–F57, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  122. R. R. Foster, R. Hole, K. Anderson et al., “Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes,” American Journal of Physiology, vol. 284, no. 6, pp. F1263–F1273, 2003. View at Google Scholar · View at Scopus
  123. D. Veron, K. J. Reidy, C. Bertuccio et al., “Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease,” Kidney International, vol. 77, no. 11, pp. 989–999, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  124. C. H. Ku, K. E. White, A. Dei Cas et al., “Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice,” Diabetes, vol. 57, no. 10, pp. 2824–2833, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  125. F. Guan, G. Villegas, J. Teichman, P. Mundel, and A. Tufro, “Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP,” American Journal of Physiology, vol. 291, no. 2, pp. F422–F428, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  126. J. Müller-Deile, K. Worthmann, M. Saleem, I. Tossidou, H. Haller, and M. Schiffer, “The balance of autocrine VEGF-A and VEGF-C determines podocyte survival,” American Journal of Physiology, vol. 297, no. 6, pp. F1656–F1667, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus